Page last updated: 2024-12-11

cefozopran

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID9571080
CHEMBL ID1276663
CHEBI ID3502
SCHEMBL ID49106
MeSH IDM0192891

Synonyms (28)

Synonym
sce 2787
cefozopran (inn)
D01052
czop
ccris 6737
cefozopran [inn]
(-)-1-(((6r,7r)-7-(2-(5-amino-1,2,4-thiadiazol-3-yl)glyoxylamido)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-1h-imidazo(1,2-b)pyridazin-4-ium hydroxide inner salt, 7(sup 2)-(z)-(o-methyloxime)
imidazo(1,2-b)pyridazinium, 1-((7-(((5-amino-1,2,4-thiadiazol-3-yl)(methoxyimino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-, inner salt, (6r-(6alpha,7beta(z)))-
imidazo(1,2-b)pyridazinium, 1-((6r,7r)-7-(((2z)-(5-amino-1,2,4-thiadiazol-3-yl)(methoxyimino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-, inner salt
chebi:3502 ,
CHEMBL1276663
unii-1lg87k28lw
1lg87k28lw ,
AKOS015896118
cefozopran hydrochloride [jan]
cefozopran [who-dd]
(-)-1-(((6r,7r)-7-(2-(5-amino-1,2,4-thiadiazol-3-yl)glyoxylamido)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-1h-imidazo(1,2-b)pyridazin-4-ium hydroxide inner salt, 7^2-(z)-(o-methyloxime)
cefozopran [mi]
HY-B0771
SCHEMBL49106
1-[[(6r,7r)-7-[[(2z)-(5-amino-1,2,4-thiadiazol-3-yl)(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3 -yl]methyl]-imidazo[1,2-b]pyridazinium hydroxide inner salt
J-504081
cefozopranum
(6r,7r)-7-{[(2z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(methoxyimino)acetyl]amino}-3-(imidazo[1,2-b]pyridazin-1-ium-1-ylmethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
7-{[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-(imidazo[1,2-b]pyridazin-1-ium-1-ylmethyl)-3,4-didehydrocepham-4-carboxylate
DB13667
imidazo[1,2-b]pyridazinium,1-[[(6r,7r)-7-[[(2z)-(5-amino-1,2,4-thiadiazol-3-yl)(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-, inner salt
DTXSID701025943

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"Human pharmacokinetic parameters are often predicted prior to clinical study from in vivo preclinical pharmacokinetic data."( Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
Jolivette, LJ; Ward, KW, 2005
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (3)

ClassDescription
cephalosporinA class of beta-lactam antibiotics differing from the penicillins in having a 6-membered, rather than a 5-membered, side ring. Although cephalosporins are among the most commonly used antibiotics in the treatment of routine infections, and their use is increasing over time, they can cause a range of hypersensitivity reactions, from mild, delayed-onset cutaneous reactions to life-threatening anaphylaxis in patients with immunoglobulin E (IgE)-mediated allergy.
thiadiazoles
imidazopyridazineAn organic heterobicyclic compound that consists of an imidazole ring ortho-fused to a pyridazine ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (63)

Assay IDTitleYearJournalArticle
AID535640Antimicrobial activity against Group B streptococcus serotype Ib C2 harboring E63K mutation in PBP 2A and L41S mutation in PBP 1B by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.
AID535646Antimicrobial activity against Group B Streptococcus serotype III NEM 316 by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.
AID1335622AUC (0 to infinity) in monkey at 20 mg/kg, iv administered as bolus dose by HPLC method2016European journal of medicinal chemistry, Nov-29, Volume: 124Novel broad-spectrum and long-acting parenteral cephalosporins having an acyl cyanamide moiety at the C-3 terminal: Synthesis and structure-activity relationships.
AID543423Antimicrobial activity against Escherichia coli XL-1 Blue transconjugant harboring beta-lactamase CTX-M-64 by broth microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
AID534379Antibacterial activity against Citrobacter freundii KHM243 clinical isolate by microdilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID540218Clearance in monkey after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID535636Antimicrobial activity against Group B streptococcus serotype VI R4 harboring Q557E mutation in PBP 2X and T567I, Y262N mutations in PBP 2B by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.
AID540216Clearance in dog after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID535644Antimicrobial activity against Group B streptococcus serotype Ib N2 harboring E63K mutation in PBP 2A and L41S mutation in PBP 1B by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1335615Antibacterial activity against methicillin-resistant Staphylococcus aureus SR36262016European journal of medicinal chemistry, Nov-29, Volume: 124Novel broad-spectrum and long-acting parenteral cephalosporins having an acyl cyanamide moiety at the C-3 terminal: Synthesis and structure-activity relationships.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID534388Antibacterial activity against Escherichia coli JM109 harboring recombinant pKHM-1 by microdilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID535637Antimicrobial activity against Group B streptococcus serotype Ib R3 harboring Q557E, A400V mutations in PBP 2X and T567I, G539E mutations in PBP 2B by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.
AID1335619AUC (0 to infinity) in mouse at 20 mg/kg, iv administered as bolus dose by HPLC method2016European journal of medicinal chemistry, Nov-29, Volume: 124Novel broad-spectrum and long-acting parenteral cephalosporins having an acyl cyanamide moiety at the C-3 terminal: Synthesis and structure-activity relationships.
AID535635Antimicrobial activity against Group B streptococcus serotype VI R5 harboring F395L, V405A, R433H, H438Y, and G648A mutations in PBP 2X and T567I mutation in PBP 2B by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.
AID1335616Antibacterial activity against Escherichia coli NIHJ JC-22016European journal of medicinal chemistry, Nov-29, Volume: 124Novel broad-spectrum and long-acting parenteral cephalosporins having an acyl cyanamide moiety at the C-3 terminal: Synthesis and structure-activity relationships.
AID543415Antimicrobial activity against rifampicin-resistant Escherichia coli X1037 transconjugant by broth microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
AID535643Antimicrobial activity against Group B streptococcus serotype III N3 by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID535634Antimicrobial activity against Group B streptococcus serotype VI R6 harboring F395L, V405A, R433H, H438Y, A374V and G648A mutations in PBP 2X and T567I mutation in PBP 2B by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.
AID540220Clearance in human after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID1335614Antibacterial activity against methicillin-resistant Staphylococcus aureus SR20302016European journal of medicinal chemistry, Nov-29, Volume: 124Novel broad-spectrum and long-acting parenteral cephalosporins having an acyl cyanamide moiety at the C-3 terminal: Synthesis and structure-activity relationships.
AID1335623Half life in monkey at 20 mg/kg, iv administered as bolus dose by HPLC method2016European journal of medicinal chemistry, Nov-29, Volume: 124Novel broad-spectrum and long-acting parenteral cephalosporins having an acyl cyanamide moiety at the C-3 terminal: Synthesis and structure-activity relationships.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID534385Antibacterial activity against Escherichia coli K-12 W1895 by microdilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate.
AID535647Antimicrobial activity against Group B Streptococcus serotype V 2603 V/R harboring E63K mutation in PBP 2A and L41S mutation in PBP 1B by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID534382Antibacterial activity against Escherichia coli K-12 W1895 transconjugant harboring pCF243 by microdilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate.
AID535633Antimicrobial activity against Group B streptococcus serotype Ia R7 harboring T77I, F395V and S353F in PBP 2X; V80A and G613R in PBP 2B; and L45P, N163K, N723S and Y470F in PBP 1A by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1335620Half life in mouse at 20 mg/kg, iv administered as bolus dose by HPLC method2016European journal of medicinal chemistry, Nov-29, Volume: 124Novel broad-spectrum and long-acting parenteral cephalosporins having an acyl cyanamide moiety at the C-3 terminal: Synthesis and structure-activity relationships.
AID540215Volume of distribution at steady state in rat after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID534391Antibacterial activity against Escherichia coli JM109 by microdilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate.
AID540217Volume of distribution at steady state in dog after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID535642Antimicrobial activity against Group B streptococcus serotype VI N4 harboring E63K mutation in PBP 2A and L41S mutation in PBP 1B by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.
AID540221Volume of distribution at steady state in human after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID535632Antimicrobial activity against Group B streptococcus R8 harboring T77I, S353F and A514V in PBP 2X; V80A and G613R in PBP 2B; and L45P, N163K, N723S and G527V in PBP 1A by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID535645Antimicrobial activity against Group B Streptococcus serotype Ia N1 harboring E63K mutation in PBP 2A and L41S mutation in PBP 1B by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.
AID543419Antimicrobial activity against rifampicin-resistant Escherichia coli X1037 by broth microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
AID543411Antimicrobial activity against Shigella sonnei UIH-1 expressing beta-lactamase CTX-M-64 by broth microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
AID1335613Antibacterial activity against Staphylococcus aureus SMITH2016European journal of medicinal chemistry, Nov-29, Volume: 124Novel broad-spectrum and long-acting parenteral cephalosporins having an acyl cyanamide moiety at the C-3 terminal: Synthesis and structure-activity relationships.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID535639Antimicrobial activity against Group B streptococcus serotype VI R1 harboring F395L, V405A, R433H, H438Y, and G648A mutations in PBP 2X and T567I mutation in PBP 2B by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.
AID535641Antimicrobial activity against Group B streptococcus serotype V C1 harboring E63K mutation in PBP 2A and L41S mutation in PBP 1B by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.
AID540219Volume of distribution at steady state in monkey after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID543427Antimicrobial activity against Escherichia coli XL-1 Blue harboring plasmid CL1920 by broth microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID540214Clearance in rat after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID1335617Antibacterial activity against Pseudomonas aeruginosa PAO12016European journal of medicinal chemistry, Nov-29, Volume: 124Novel broad-spectrum and long-acting parenteral cephalosporins having an acyl cyanamide moiety at the C-3 terminal: Synthesis and structure-activity relationships.
AID535638Antimicrobial activity against Group B streptococcus serotype VI R2 harboring F395L, V405A, R433H, H438Y, and G648A mutations in PBP 2X and T567I mutation in PBP 2B by broth microdilution method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Genetic heterogeneity in pbp genes among clinically isolated group B Streptococci with reduced penicillin susceptibility.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1335618Antibacterial activity against Pseudomonas aeruginosa SA242016European journal of medicinal chemistry, Nov-29, Volume: 124Novel broad-spectrum and long-acting parenteral cephalosporins having an acyl cyanamide moiety at the C-3 terminal: Synthesis and structure-activity relationships.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (80.00)29.6817
2010's1 (20.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 36.46

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index36.46 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.30 (4.65)
Search Engine Demand Index45.20 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (36.46)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]